Results 111 to 120 of about 5,090 (179)

The Evolution, Current Landscape, and Future Prospects of Oncolytic Virotherapy in Melanoma: Talimogene Laherparepvec and Beyond. [PDF]

Cells
Smestad J, Rieth J, Laux D, Milhem M.
europepmc   +1 more source

Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial.

JAMA Oncol, 2023
Dummer R, Gyorki DE, Hyngstrom JR, Ning M, Lawrence T, Ross MI.   +5 more
europepmc   +1 more source

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec

JAAD Case Reports, 2017
Jonathan T. Blackmon, Michael S. Stratton, MD, Young Kwak, MD, Peter G. Pavlidakey, MD, Andrzej T. Slominski, MD, Svetlana B. McKee, RN, BSN, Toni M. Viator, RN, Ju Young Kim, PhD, Conway C. Huang, MD, Robert M. Conry, MD   +9 more
doaj   +1 more source

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO). [PDF]

Nat Commun
Pascual T, Vidal M, Cejalvo JM, Vega E, Sanfeliu E, Villacampa G, Ganau S, Parreño AMJ, Zamora E, Miranda I, Delgado A, Bermejo B, Seguí E, Brasó-Maristanty F, de la Cruz-Merino L, Juan M, Galván P, Gonzàlez-Farré X, Chillara S, Villagrasa P, Pfefferle AD, O'Connell CE, Ferrero-Cafiero JM, Oliveira M, Perou CM, Prat A.   +25 more
europepmc   +1 more source

Intralesional Talimogene Laherparepvec Immunotherapy for Melanoma: A Case Study. [PDF]

Cureus
Ghebrehiwet M, Pavlis J, Gomez-Meade C.
europepmc   +1 more source

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. [PDF]

J Immunother Cancer, 2023
Chesney JA, Puzanov I, Collichio FA, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan T, Hauschild A, Lebbé C, Joshi H, Snyder W, Mehnert JM.   +15 more
europepmc   +1 more source

Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. [PDF]

NPJ Breast Cancer
Huppert LA, Gliwa AS, Tait M, Quintal L, Starzinski S, Cheung A, Moasser M, Majure M, Melisko M, Munster P, Rugo HS, Campbell M, Fong L, Chien AJ.   +13 more
europepmc   +1 more source

Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2. [PDF]

Ther Adv Med Oncol
Reitmajer M, Nanz L, Müller N, Leiter U, Amaral T, Aebischer V, Flatz L, Forschner A.   +7 more
europepmc   +1 more source

Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma. [PDF]

Cureus, 2022
Wolfe Z, Blackham A, McIntosh A, Miller A, Sheikh H, Nair S.   +5 more
europepmc   +1 more source

Clinical Improvement of Treatment-Resistant Metastatic Basal Cell Carcinoma After Intratumoral Injection of Talimogene Laherparepvec. [PDF]

Dermatol Surg
Che Y, Abou-Taleb F, Reddy SA, Chang ALS.   +3 more
europepmc   +1 more source